Beta Bionics, Inc. (BBNX)
Nasdaq: BBNX · Surgical & Medical Instruments & Apparatus · Irvine, CA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Feb 24, 2026 | Mar 25, 2025 | · |
| Revenue | 100,251 | 65,124 | 11,995 |
| Cost of revenue | 44,714 | 29,236 | 5,687 |
| Gross profit | 55,537 | 35,888 | 6,308 |
| Research and development | 34,789 | 26,184 | 17,943 |
| Sales and marketing | 61,404 | 37,086 | 11,990 |
| General and administrative | 31,025 | 17,869 | 12,225 |
| Total operating expenses | 127,218 | 81,139 | 42,158 |
| Operating income | -71,681 | -45,251 | -35,850 |
| Interest and investment income | 10,932 | 3,909 | 1,777 |
| Other income (expense), net | -1 | -2 | -68 |
| Total non-operating income (expense) | -1,519 | -9,505 | -8,249 |
| Income tax expense | 0 | 0 | · |
| Net income | -73,200 | -54,756 | -44,099 |
| Earnings per share, basic | -1.81 | -8.60 | -8.31 |
| Earnings per share, diluted | -1.81 | -8.60 | -8.31 |
| Weighted average shares, basic | 40,529,051 | 6,365,064 | 5,303,684 |
| Weighted average shares, diluted | 40,529,051 | 6,365,064 | 5,303,684 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding